During the corresponding time, Zomedica Corp recorded a revenue increase by 32.42 % year on year, sequentially revenue fell by -18.98 %. While revenue at the Zomedica Corp 's corporate clients
Zomedica's Comment on Sales, Marketing and Customers
The company provides diagnostic and therapeutic technologies to veterinarians and pet owners, focusing on enhancing pet care quality, customer satisfaction, and veterinary practice efficiency. Its market includes domestic animal health distributors, online retailers, and international subsidiaries and distribution channels. The company offers six product lines of diagnostic and therapeutic devices, including the TRUFORMA Bulk Acoustic Wave point-of-care diagnostic platform, which features assays for feline optimized TSH, canine endogenous ACTH, canine Free T4, a multiplex cartridge for canine and feline cobalamin and folate, equine endogenous ACTH, canine NT-proBNP, canine progesterone, equine insulin, equine cortisol, and canine TSH. Additional products include the VETGuardian PLUS Zero Touch vital signs remote monitoring system, the TRUVIEW digital microscopy platform, and VETIGEL, a hemostatic gel licensed from Cresilon, Inc. The company serves veterinarians and pet owners through multiple purchasing channels and seeks to expand its revenue and product portfolio through acquisitions and internal development.
Zomedica’s Comment on Sales, Marketing and Customers
The company provides diagnostic and therapeutic technologies to veterinarians and pet owners, focusing on enhancing pet care quality, customer satisfaction, and veterinary practice efficiency. Its market includes domestic animal health distributors, online retailers, and international subsidiaries and distribution channels. The company offers six product lines of diagnostic and therapeutic devices, including the TRUFORMA Bulk Acoustic Wave point-of-care diagnostic platform, which features assays for feline optimized TSH, canine endogenous ACTH, canine Free T4, a multiplex cartridge for canine and feline cobalamin and folate, equine endogenous ACTH, canine NT-proBNP, canine progesterone, equine insulin, equine cortisol, and canine TSH. Additional products include the VETGuardian PLUS Zero Touch vital signs remote monitoring system, the TRUVIEW digital microscopy platform, and VETIGEL, a hemostatic gel licensed from Cresilon, Inc. The company serves veterinarians and pet owners through multiple purchasing channels and seeks to expand its revenue and product portfolio through acquisitions and internal development.
Sources:
Zomedica Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Zomedica Corp’s corporate clients.
For your research, we’ve provided 9 tables on Zomedica Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.